| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6000399 | Thrombosis Research | 2016 | 32 Pages |
Abstract
PRn exhibits higher antithrombotic potency and longer half-life in vivo as compared with native Rn on a molar basis. In addition, PRn exhibits a better safety profile at an efficacious antithrombotic dose in vivo. Therefore, PEGylation may be one of the ideal options in modifying disintegrin derivatives as the safe therapeutic agents for integrin-related diseases.
Keywords
PGE1PRNMCFPPPPEGylationCFTPrPACDROTEMt1/2acid citrate dextroseSDS-PAGESodium dodecyl sulfate polyacrylamide gel electrophoresisintegrin αIIbβ3analysis of varianceANOVAMaximum clot firmnessalpha angleClot formation timeClotting timeAnti-thrombosisDisintegrinHalf-lifeProstaglandin E1platelet-poor plasmaplatelet-rich plasmaPlateletpolyethylene glycolPEG
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Chun-Chieh Hsu, Woei-Jer Chuang, Ching-Hu Chung, Chien-Hsin Chang, Hui-Chin Peng, Tur-Fu Huang,